There are currently 1094 clinical trials in Rochester, Minnesota looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic, Mayo Clinic in Rochester, Mayo Clinic - Rochester and Mayo Clinic Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078
Recruiting
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Acquired Hemophilia A
Register for Updates
CONVERGE Post-Approval Study (PAS)
NCT05393180
Recruiting
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Chronic Atrial Fibrillation
Register for Updates
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
NCT05928390
Recruiting
The Total duration of trial participation for each participant with post-bariatric hypoglycemia will be a maximum of 59 weeks, with the following duration of trial periods * 19 weeks for the Core Phase. It is composed of: * a Screening period: a maximum of 3 weeks * a Run-in period (no treatment): 4 weeks * a Blinded Treatment Phase: 12 weeks * 36 weeks Extension Phase = an open-label Treatment period * 4 weeks for the safety follow-up period (without any treatment).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic - Rochester, 200 First Street, SW, 55905, Rochester, Minnesota
Conditions: Post-Bariatric Hypoglycemia
Register for Updates
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
NCT06770049
Recruiting
The purpose of this study is to develop an evidence-based precision medicine approach for obesity that enhances weight loss and promotes weight loss maintenance.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Obesity
Register for Updates
Treatment of Upper Gastrointestinal Symptoms Using Hypnotherapy Sessions
NCT06846359
Recruiting
The purpose of this research is to evaluate if hypnotherapy delivered digitally will help your GI symptoms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: GI Symptoms
Register for Updates
Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases
NCT06870253
Recruiting
The goal of this observational study is to learn about the performance of the Bladder CARE™ Assay in patients suspected of having bladder cancer with atypical cytology or equivocal cystoscopy results. The main question it aims to answer is: • Does the Bladder CARE™ Assay detect bladder cancer in patients who have inconclusive cytology or cystoscopy results? Participants will provide one voided urine specimen on the day of, and prior to, the routine, scheduled standard of care initial or repeat... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
06/02/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Bladder Cancer, Urothelial Carcinoma Bladder
Register for Updates
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
NCT04947319
Recruiting
This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: Mayo Clinic- Rochester, Rochester, Minnesota
Conditions: Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Register for Updates
Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures
NCT05076110
Recruiting
This study is being conducted to evaluate the effectiveness of post-operative pain control without using narcotic pain medications.
Gender:
ALL
Ages:
Between 16 years and 60 years
Trial Updated:
05/30/2025
Locations: Mayo clinic, Rochester, Minnesota
Conditions: Hip Arthroscopy
Register for Updates
Glucagon Suppression by Hyperglycemia in the Presence and Absence of Amino Acid Infusion
NCT05264727
Recruiting
This study is being done to better understand how amino acids alter the release of glucagon and insulin compared to glucose alone in health and disease.
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
05/30/2025
Locations: Mayo Clinic Rochester, Rochester, Minnesota
Conditions: Healthy, Type 2 Diabetes, Obesity
Register for Updates
The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction
NCT05499702
Recruiting
Caloric restriction (and RYGB) improves insulin action and lowers fasting glucose, glucagon and EGP, without changes in postprandial EGP and glucagon concentrations. Caloric restriction also improves hepatic steatosis and lowers fasting AA. These changes may represent restoration of glucagon's hepatic actions. This experiment will determine whether caloric restriction improves glucagon's actions on hepatic amino acid, carbohydrate and lipid metabolism in T2DM in comparison to a baseline experime... Read More
Gender:
ALL
Ages:
Between 25 years and 65 years
Trial Updated:
05/30/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Type2diabetes
Register for Updates
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387
Recruiting
This phase III trial compares three-drug induction regimens followed by double-or single-drug maintenance therapy for the treatment of newly diagnosed multiple myeloma in patients who are not receiving a stem cell transplant and are considered frail or intermediate-fit based on age, comorbidities, and functional status. Treatment for multiple myeloma includes initial treatment (induction) which is the first treatment a patient receives for cancer followed by ongoing treatment (maintenance) which... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/29/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Plasma Cell Myeloma
Register for Updates